Shares of Repros Therapeutics Inc. (NASDAQ:RPRX) saw unusually-strong trading volume on Wednesday . Approximately 627,387 shares traded hands during trading, an increase of 60% from the previous session’s volume of 393,198 shares.The stock last traded at $2.28 and had previously closed at $2.07.

Separately, Zacks Investment Research cut shares of Repros Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 13th. One investment analyst has rated the stock with a sell rating and four have given a hold rating to the stock. Repros Therapeutics currently has an average rating of “Hold” and an average price target of $21.50.

The company has a 50-day moving average of $1.73 and a 200 day moving average of $1.54. The firm’s market cap is $53.26 million.

Repros Therapeutics (NASDAQ:RPRX) last posted its earnings results on Tuesday, May 10th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.02. Equities analysts predict that Repros Therapeutics Inc. will post ($0.75) EPS for the current fiscal year.

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include Androxal and Proellex. The Company’s primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.